Drugs / JNJ-64530440
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03890341 | Jun → Aug 2021 | — | Janssen Research & Development, LLC | Withdrawn | No outcome recorded Stop: Business |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JNJ-64530440 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03890341 ↗ |
| Route | Oral | “A single oral dose of JNJ-64530440 2,000 mg will be administered on Day 6 and once daily on Days 13 to 22.” NCT03890341 ↗ |